Elicera Therapeutics AB

ELIC

SE0015382080

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 28/06/2024 BST			5-day change	1st Jan Change
1.29 ^SEK	-7.86%		-10.42%	-71.71%

06-11	Elicera Therapeutics Enters A Preclinical Collaboration Agreement with China Medical University for the Development of Elc-201	CI
05-29	Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA	CI

BioStock: Elicera teams up with China Medical University for cancer study

June 17, 2024 at 07:47 am

Elicera Therapeutics has announced a new research collaboration with the Fourth Affiliated Hospital of China Medical University to assess the efficacy of oncolytic virus ELC-201 in preclinical proof-of-concept studies. This collaboration will explore the potential of ELC-201 across various solid tumour indications. BioStock turned to Elicera's CEO Jamal El-Mosleh to learn more.

Read the article at biostock.se:

Elicera teams up with China Medical University for cancer study - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/elicera-therapeutics/r/biostock--elicera-teams-up-with-china-medical-university-for-cancer-study,c4001251

Latest news about Elicera Therapeutics AB

Elicera Therapeutics Enters A Preclinical Collaboration Agreement with China Medical University for the Development of Elc-201	06-11	CI
Elicera Therapeutics Set to Begin First Clinical CAR T-Cell study CARMA	05-29	CI
Elicera Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-27	CI
Elicera Therapeutics AB Announces Director Changes	03-28	CI
Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies	03-06	CI
Elicera Therapeutics AB to Present at the Scientific Conference International Society for Cell & Gene Therapy Meeting 2024 in Vancouver, Canada, May 28 to June 1	02-16	CI
Elicera Therapeutics AB Receives Conditional Approval from the Medical Products Agency on Its Car T-Cell Clinical Trial Application to Test ELC-301	02-14	CI
Elicera Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-13	CI
Elicera Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-13	CI
Swedish Regulator OKs Elicera’s Clinical Trial for Lymphoma Therapy	02-09	MT
Elicera Therapeutics Receives Approval to Initiate Clinical Phase I/II-Study Carma with Car T-Cell Therapy ELC-301 in B-Cell Lymphoma	02-09	CI
Elicera Therapeutics AB Participates in A Collaborative Project for the Development of Improved Car T-Cell Production That Has Been Awarded Research Support of SEK 850 Thousand	01-09	CI
Elicera Therapeutics AB Co-Founder Receives Grant Totalling 4.8 million SEK from the Swedish Childhood Cancer Fund to Support Car T-Cell Research	12-22	CI
Elicera Therapeutics AB Submits GMP Validation Data to the Swedish Medical Products Agency for the CARMA Study to Supplement the Conditionally Approved Clinical Trial Application	12-22	CI
Elicera Therapeutics AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Elicera Therapeutics AB Announces That Representatives of the Largest Owners Appoints the Nomination Committee Ahead of the Annual General Meeting 2024	31/10/23	CI
Elicera Therapeutics to Receive Chinese Patent for iTANK Platform	08/09/23	MT
Elicera Therapeutics Receives Notice of Allowance for Chinease Patent Protecting the iTANK Platform	08/09/23	CI
Elicera Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/08/23	CI
Elicera Therapeutics AB Announces the Publication of a Scientific Article in the ELC-401 Program	10/08/23	CI
Elicera Therapeutics to Receive European Patent for iTANK Platform	11/07/23	MT
Elicera Therapeutics AB Receives Notice of Allowance for European Patent Protecting the iTANK	11/07/23	CI
Elicera Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2023	16/05/23	CI
Elicera Therapeutics AB Receives Conditional Approval from the Medical Products Agency on its CAR T-Cell Clinical Trial Application to Test ELC-301 (CARMA- Study)	28/04/23	CI
Elicera Therapeutics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	17/02/23	CI

Chart Elicera Therapeutics AB

Duration

Period

More charts

Company Profile

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The Company is developing next-generation cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.

Sector

Pharmaceuticals

Calendar

15/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELICERA THERAPEUTICS AB	-71.71%	4.27M
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+44.05%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
ROCHE HOLDING AG	+2.04%	224B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B

Other Pharmaceuticals

Elicera Therapeutics AB

Equities

ELIC

SE0015382080

Pharmaceuticals

BioStock: Elicera teams up with China Medical University for cancer study

Latest news about Elicera Therapeutics AB

Chart Elicera Therapeutics AB

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals